ARTICLE | Company News
KeyBioscience grants Lilly rights to Type II diabetes platform
June 23, 2017 7:39 PM UTC
The KeyBioscience AG subsidiary of Nordic Bioscience A/S (Herlev, Denmark) granted Eli Lilly and Co. (NYSE:LLY) worldwide rights to develop and commercialize its Dual Amylin Calcitonin Receptor Agonist (DACRA) platform to develop compounds to treat metabolic disorders, including Type II diabetes.
KeyBioscience will receive a $55 million upfront payment and is eligible for milestones and royalties. The deal includes KBP-042, KBP-089 and KBP-056, plus additional compounds in preclinical and Phase I development. KeyBioscience has initiated a Phase II trial of KBP-042...